▶주메뉴 바로가기

▶본문 바로가기

검색폼

THE INVESTOR

Market Now

Yungjin Pharm renews W181.6b contract with Japan’s Sawai

  • PUBLISHED :March 21, 2017 - 09:27
  • UPDATED :March 21, 2017 - 09:27
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print
[DISCLOSURE] Yungjin Pharmaceutical (003520) announced on March 20 that it has renewed its contract with Japan’s Sawai Pharmaceutical to exclusively supply oral antibiotics. 

The contract is worth 181.6 billion won (US$162.72 million), amounting to 106.7 percent of its 2015 revenue. It is valid until Dec. 31, 2021, to be automatically renewed every year without objection from either party. 

By Hwang You-mee (theinvestor@heraldcorp.com)

  • facebook
  • twitter
  • sms
  • print

TOP NEWS